Fundraising Fox

Latigo Bio

Thousand Oaks, US · 6 known investors

Latigo Biotherapeutics is a clinical-stage biopharmaceutical company developing non-opioid pain medicines designed to stop pain transmission without addiction risk. The company aims to build a broad pipeline of pain therapeutics by leveraging its team's expertise in pain biology and clinical development.

BiotechHealthtechMedical Devices

Founders & leadership

NFNima Farzan
Nima FarzanExecutive
TLTim Lugo
Tim LugoExecutive

Board

BSBeth Seidenberg
Beth Seidenbergin𝕏Board directorFounding Managing Director at Westlake Village BioPartners
JT
Jim TananbaumBoard director
DPDeborah Palestrant
Deborah PalestrantinBoard directorPartner, Executive Chair, 4:59 Initiative at 5AM Ventures
KR
Kevin RaidyBoard director
NS
Nancy StaglianoBoard director
TW
Tim WalbertBoard director

Investors · 6

Access BiotechnologyNew York City
Foresite CapitalWest Hollywood
Kern Capital, LLCLarkspur · $5M – $15Mvia Jay Kern · inferred
Sanofi VenturesCambridge · $5M
5AM VenturesreportedBoston · $100K – $4Mvia Deborah Palestrant · board
Westlake Village BioPartnersreportedLos Angeles · $100K – $5Mvia Beth Seidenberg · board

Funding

SEC filings, press & company announcements

$395.6M disclosed across 2 rounds · 2025–2026

▶$50MraisedFeb 2025 · 7 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Nancy StaglianoDirector
  • Beth SeidenbergDirector
  • Nima FarzanExecutive Officer, Director
  • Jim TananbaumDirector
  • Deborah PalestrantDirector
  • Kevin RaidyDirector
  • Tim LugoExecutive Officer
  • Tim WalbertDirector
Offering amount
$150M
Amount sold
$50M
First sale
Jan 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Latigo Nets $346 Million from Public Offering - Los Angeles Business Journallabusinessjournal.com · Aug 2026Latigo Bio IPO exceeds expectations | Pacific Coast Business Timespacbiztimes.com · Aug 2026Latigo priced its IPO at $18 a share for $345.6 million, one of the largest biotech raises of the year and… | 24/7 Wall St.247wallst.com · Aug 2026Latigo IPO raises nearly $350M for pain drug development | BioPharma Divebiopharmadive.com · Aug 2026Non-Opioid Painkiller Maker Latigo Raises $345.6 Million in IPO - Bloombergbloomberg.com · Aug 2026Latigo Biotherapeutics raises $345.6M in IPOaxios.com · Aug 2026Sell or Invest in Latigo Bio Stock Pre-IPOnasdaqprivatemarket.com · Apr 2025

Frequently asked questions

What does Latigo Bio do?
Latigo Biotherapeutics is a clinical-stage biopharmaceutical company developing non-opioid pain medicines designed to stop pain transmission without addiction risk. The company aims to build a broad pipeline of pain therapeutics by leveraging its team's expertise in pain biology and clinical development.
Who are Latigo Bio's investors?
Latigo Bio's investors include Access Biotechnology, Foresite Capital, Kern Capital, LLC, Sanofi Ventures, 5AM Ventures, Westlake Village BioPartners.
How much funding has Latigo Bio raised?
Latigo Bio has disclosed $395.6M raised across 2 rounds.
Where is Latigo Bio headquartered?
Latigo Bio is headquartered in Thousand Oaks, US.